|
1. Kim JE, Chung BY, Sim CY, Park AY, Lee JS, Whang KU, et al. Clinicopathologic features and prognostic factors of primary cutaneous melanoma: A multicenter study in Korea. J Korean Med Sci. 2019; 34(16): e126. doi: 10.3346/jkms.2019.34.e126. 2. Shi J, Kantoff PW, Wooster R, Farokhzad OCJNrc. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017; 17(1):20-37. doi: 10.1038/nrc.2016.108. Epub 2016 Nov 11. 3. Tahergorabi Z, Khazaei MJIjobms. A review on angiogenesis and its assays. Iran J Basic Med Sci. 2012; 15(6):1110-26. 4. Bando H. Vascular endothelial growth factor and bevacitumab in breast cancer. Breast cancer (Tokyo, Japan). Breast Cancer. 2007; 14(2):163-73. doi: 10.2325/jbcs.968. 5. Nakatsu MN, Sainson RC, Pérez-del-Pulgar S, Aoto JN, Aitkenhead M, Taylor KL, et al. VEGF121 and VEGF165 regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. Lab Invest. 2003; 83(12): 1873-85. doi: 10.1097/01.lab.0000107160.81875.33. 6. Ellis LM, Hicklin DJJNrc. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8): 579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3. 7. Karthic A, Roy A, Lakkakula J, Alghamdi S, Shakoori A, Babalghith AO, et al. Cyclodextrin nanoparticles for diagnosis and potential cancer therapy: A systematic review. Front Cell Dev Biol. 2022; 10: 984311. 8. Elbe H, Yigitturk G, Cavusoglu T, Uyanikgil Y, Ozturk F. Apoptotic effects of thymol, a novel monoterpene phenol, on different types of cancer. Bratisl Lek Listy. 2020; 121(2): 122-8. 9. Shabestarian H, Homayouni M, Movahedi M, Neamati A, Sharifnia F. Green Synthesis and Comparison of Biological Properties of Ag-NPs as a Metal Nanoparticle with ZnO-NPs as a Metal Oxide Nanoparticle and their Applications2022. 10. McDonald ES, Clark AS, Tchou J, Zhang P, Freedman GM. Clin Diagnosis Management Breast Cancer. J Nucl Med. 2016; 57 Suppl 1:9s-16s. 11. Viac J, Schmitt D, Claudy AJCl. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett. 1998; 125(1-2): 35-8. 12. Aydın E, Turkez H, Tasdemir S, Hacımuftuoglu FJCNSAiMC. Anticancer, antioxidant and cytotoxic potential of thymol in vitro brain tumor cell model. Cent Nerv Syst Agents Med Chem. 2017; 17(2): 116-22.doi: 10.2174/1871524916666160823121854.2017; 13. Stryker ZI, Rajabi M, Davis PJ, Mousa SA. Evaluation of Angiogenesis Assays. Biomedicines. 2019; 7(2): 37. doi: 10.3390/biomedicines7020037. 14. Abed RM. Cytotoxic, cytogenetics and immunomodulatory effects of thymol from Thymus vulgaris on cancer and normal cell lines in vitro and in vivo. Al-Mustansiriyah J Sci. 2011; 22(4): 41-53.
|
.png){kind=logo}
